TITLE: Oral Progesterone for the Treatment of Menopausal Symptoms: Clinical Evidence

DATE: 24 July 2014

RESEARCH QUESTIONS

1. What is the clinical efficacy of micronized progesterone for the management of menopausal symptoms?
2. What is the clinical efficacy of medroxyprogesterone for the management of menopausal symptoms?
3. What is the comparative clinical efficacy of micronized progesterone versus medroxyprogesterone for the management of menopausal symptoms?

KEY FINDINGS

One systematic review, 23 publications from randomized controlled trials, and two non-randomized studies were identified regarding the clinical efficacy of micronized progesterone or medroxyprogesterone, or the comparative clinical efficacy of micronized progesterone versus medroxyprogesterone, for the management of menopausal symptoms.

METHODS

A focused literature search (with main concepts appearing in title or subject heading) was conducted using key resources including PubMed, The Cochrane Library (2014, Issue 7), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 1995 and December 31, 2008. Internet links were provided, where available. Additional references were drawn from a previous report on the same topic, including English language documents published between January 1, 2009 and March 28, 2014.
RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials and non-randomized studies.

One systematic review, 23 publications from randomized controlled trials, and two non-randomized studies were identified regarding the clinical efficacy of micronized progesterone or medroxyprogesterone, or the comparative clinical efficacy of micronized progesterone versus medroxyprogesterone, for the management of menopausal symptoms. No relevant health technology assessments were identified.

Additional references of potential interest are provided in the appendix.

Health Technology Assessments
No literature identified.

Systematic Reviews and Meta-analyses


Randomized Controlled Trials


Non-Randomized Studies


PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Randomized Controlled Trials

Alternate Outcome


Non-Randomized Studies

Mixed Treatment Regimen


Qualitative Research


Review Articles


